Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2939 • 2014 ACR/ARHP Annual Meeting
Increased Diagnosis of Spondyloarthritis in Female Patients Started in the Early Biologic Era
Nisha Nigil Haroon¹, Ping Li², Michael Paterson² and Nigil Haroon³, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose The health and economic impact of spondyloarthritis is considerable and growing. Over the past decade or more, there have been two major changes in…
Abstract Number: 2579 • 2014 ACR/ARHP Annual Meeting
How Should We Calculate the ASDAS If the Conventional C-Reactive Protein Is below the Limit of Detection? – an Analysis in the DESIR Cohort
Pedro Machado^1,2, Victoria Navarro-Compán^1,3, Robert Landewé^4,5, Floris van Gaalen¹, Christian Roux⁶ and Desirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University College London, London, United Kingdom, ³University Hospital La Paz, Madrid, Spain, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Atrium Medical Center, Heerlen, Netherlands, ⁶Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite measure of disease activity in axial spondyloarthritis. It was suggested that when the conventional …
Abstract Number: 1598 • 2014 ACR/ARHP Annual Meeting
Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis
Hanna Przepiera-Bedzak¹, Katarzyna Fischer² and Marek Brzosko¹, ¹Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland, ²Independent Laboratory of Rheumatic Diagnostics, Pomeranian Medical University in Szczecin, Szczecin, Poland
Background/Purpose In recent years, increased incidences of metabolic disorders have been observed in patients with systemic inflammatory rheumatic diseases. Fetuin-A, Intercellular Adhesion Molecule -1(ICAM-1) and…
Abstract Number: 606 • 2014 ACR/ARHP Annual Meeting
The Immunological Basis of the Sex-Bias in Ankylosing Spondylitis: Th17 Expansion Is Restricted to Male Patients and Correlates with Sex-Related Alteration in Vitamin D Metabolism
Eric Gracey^1,2, Blerta Green², Paul Yip³, Renise Ayearst⁴, Ammepa Anton⁵, Aifeng Lin² and Robert D. Inman⁶, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, University Health Network, Toronto, ON, Canada, ³Clinical Biochemistry, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, Toronto, ON, Canada, ⁶Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose : Ankylosing spondylitis (AS) is an inflammatory arthritis of the spine, which has a major impact on function and quality of life. AS is…
Abstract Number: 569 • 2014 ACR/ARHP Annual Meeting
Better Outcomes in Ankylosing Spondylitis: The Synergistic Association Between Exercise and Tumor Necrosis Factor Inhibitors
Sarah L. Patterson¹, John D. Reveille^2,3, MinJae Lee⁴, Michael M. Ward⁵, Mohammad H. Rahbar⁶, Matthew A. Brown⁷, Michael H. Weisman⁸ and Lianne S. Gensler⁹, ¹Internal Medicine, University of California, San Francisco, San Francisco, CA, ²Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁴Medicine, University of Texas Health Science Center at Houston, Houston, TX, ⁵Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ⁶The University of Texas Health Science Center at Houston, Houston, TX, ⁷University of Queensland Diamantina Institute, Brisbane, Australia, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Exercise is an important component of Ankylosing Spondylitis (AS) management. The purpose of this study was to determine if the amount patients exercise associates…
Abstract Number: 2940 • 2014 ACR/ARHP Annual Meeting
Do Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Respond Similarly Well to Nsaids? – a Prospective Study Including Magnetic Resonance Imaging
Xenofon Baraliakos¹, Uta Kiltz¹, Frank Heldmann¹, Heiner Appel², Friedrich Dybowski³, Manfred Igelmann⁴, Ludwig Kalthoff⁵, Dietmar Krause⁶, Hans-Jürgen Menne⁷, Ertan Saracbasi⁸, Elmar Schmitz-Bortz⁹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology and Nephrology Practice, Hamm, Germany, ³Rheumatology Practice, Herne, Germany, ⁴Rheumatology Practice, Bochum, Germany, ⁵Rheumatology practice, Herne, Germany, ⁶Rheumatology practice, Gladbeck, Germany, ⁷Rheumatology practice, Dortmund, Germany, ⁸Rheumatology practice, Oberhausen, Germany, ⁹Rheumatology practice, Hattingen, Germany
Background/Purpose: Patients classified as axial spondyloarthritis (axSpA) may have ankylosing spondylitis (AS) or non-radiographic axSpA (nr-axSpA). Treatment recommendations for AS consider non-steroidal anti-inflammatory drugs (NSAIDs)…
Abstract Number: 2590 • 2014 ACR/ARHP Annual Meeting
Comparison of Radiographic Damage Score in Ankylosing Spondylitis According to Tumor Necrosis Factor Inhibitor: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) Data
Tae-Jong Kim¹, JI Hui SHIN², Il-Hoon Sung³, Seunghun Lee⁴, Kyung-Bin Joo⁵ and Tae-Hwan Kim⁶, ¹Chonnam Nat`l University Medical School&Hospital, Gwangju, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Orthopaedic surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Department of Radiology, Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Department of Radiology, Department of Radiology, Hanynag University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose To evaluate the influence of tumor necrosis factor (TNF) blocker on the radiographic damage in ankylosing spondylitis (AS). Methods . A total of 610…
Abstract Number: 1599 • 2014 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes
Megan E. B. Clowse, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: While it has long been reported that rheumatoid arthritis (RA) improves with pregnancy, there is very limited information about ankylosing spondylitis (AS) or…
Abstract Number: 597 • 2014 ACR/ARHP Annual Meeting
Inflammatory Burden in Recent-Onset Axial Spondyloarthritis
Juan Jose Aznar Sánchez¹, Raul Veroz Gonzalez¹, Adela Gallego Flores¹, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez² and Eugenio Chamizo Carmona¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Mérida, Spain
Background/Purpose Patients with Non-Radiographic Axial Spondylarthritis (non-Rx AxSpA) don't presnt with different clinical manifestations than patients with Ankilosing Spondylitis (AS), although the inflammatory burden measured…
Abstract Number: 568 • 2014 ACR/ARHP Annual Meeting
Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Susana Holgado¹, Maria Lourdes Mateo¹, Juana Sanint¹, Anne Riveros-Frutos², Jeronima Cañellas¹, Xavier Tena¹ and Alejandro Olivé Marqués¹, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Secondary amyloidosis (AA) is a disorder caused by deposition of insoluble amyloid A fibrils in different tissues and organs. It is a rare and…
Abstract Number: 2827 • 2014 ACR/ARHP Annual Meeting
Cervical Spine Fracture and Mortality in Ankylosing Spondylitis
Katherine D. Wysham¹, Sara G. Murray², Nancy K. Hills³, Edward H. Yelin⁴ and Lianne S. Gensler⁵, ¹Internal Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Little data exist regarding mortality in Ankylosing Spondylitis (AS) patients. We performed a population-based study of diagnoses associated with hospital mortality in AS. Methods:…
Abstract Number: 2585 • 2014 ACR/ARHP Annual Meeting
Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis
Grigorios Sakellariou¹, Spyros Gerou², Dimitrios Oikonomou³ and Fares Sayegh⁴, ¹Rheumatology, 424 General Military Hospital, Thessaloniki, Greece, ²Laboratories "Analysis", Thessaloniki, Greece, ³Biopathology, 424 General Military Hospital, Thessaloniki, Greece, ⁴3rd Orthopaedic, "Papageorgiou" General Hospital, Thessaloniki, Greece
Background/Purpose: In patients with ankylosing spondylitis (AS), smoking is associated with increased disease activity and more radiographic damage. However, the mechanisms underlying the effects of…
Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)
Saedis Saevarsdottir¹, Michele Santacatterina², Carl Turesson³, Helena Forsblad⁴, Lennart Jacobsson⁴ and Staffan Lindblad⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…
Abstract Number: 596 • 2014 ACR/ARHP Annual Meeting
Clinical Value of ASDAS Index in Spanish Patients with Ankylosing Spondylitis
Agusti Sellas-Fernandez¹, Jose Luis Guerra Vázquez², Jose Luis Casals³, Carlos Gonzalez Fernandez⁴, Roberto Miguelez⁵, José Rosas⁶, Antonio Fernandez-Nebro⁷, Cilia Peralta Ginés⁸, Carlos Montilla-Morales⁹, Xavier Juanola¹⁰, Miguel Ángel Abad¹¹, Alberto Alonso¹², Azucena Hernández-Sanz¹³, Luis Francisco Linares¹⁴, Julio Medina¹⁵, Joana Rovira¹⁶, Juan Carlos Torre-Alonso¹⁷, Alfredo Willisch¹⁸, Eduardo Collantes-Estevez¹⁹ and Ana Ruiz-Zorrilla²⁰, ¹H. Vall d'Hebron, Barcelona, Spain, ²H. Arquitecto Marcide, La Coruña, Spain, ³H. Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵H. de Móstoles, Madrid, Spain, ⁶Rheumatology, Hospital Marina Baixa, Villajoyosa, Valencia, Alicante, Spain, ⁷Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁸H. Clínico Lozano Blesa, Zaragoza, Spain, ⁹H. de Salamanca, Salamanca, Spain, ¹⁰Rheumatology, University Hospital Bellvitge, Barcelona, Spain, ¹¹Hospital Virgen del Puerto, Cáceres, Spain, ¹²Hospital de Cruces, Bilbao, Spain, ¹³H. Virgen de la Salud, Toledo, Spain, ¹⁴Hospital Virgen de la Arrixaca., Murcia, Spain, ¹⁵Hospital Clínico, Valladolid, Spain, ¹⁶Mutua Terrasa, Barcelona, Spain, ¹⁷Rheumatology Department, H. Monte Naranco, Oviedo, Spain, ¹⁸Complexo Hospitalario de Ourense, Ourense, Spain, ¹⁹Hospital Reina Sofía, Córdoba, Spain, ²⁰Abbvie, Madrid, Spain
Background/Purpose The ASDAS (ankylosing spondylitis disease activity score) was developed to overcome some of the deficiencies of BASDAI (Bath Ankylosing Disease Activity Spondyltis Index). In…
Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
James T. Rosenbaum^1,2, Martin Rudwaleit³, Robert B. M. Landewé⁴, Helena Marzo-Ortega^5,6, Joachim Sieper⁷, Désirée M. van der Heijde⁸, Owen Davies⁹, Christian Stach¹⁰, Tommi Nurminen¹⁰ and Atul A. Deodhar¹¹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Endokrinologikum, Berlin, Germany, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumatology Department,, University Hospital Charité, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim, Germany, ¹¹Oregon Health and Sciences University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.